LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
Resmonics is developing a digital biomarker service for patients with asthma and COPD
Asthma Guardian is the company’s first product. The smartphone application monitors a patient’s breathing in real-time for signs of future exacerbations. The company recently closed a pre-seed financing round. Funds from the round will be used to accelerate market entry for the company’s digital health application, which is anticipated to reach European markets in Q3/21.
Endo Tools Therapeutics raises $9.5M in Series D round
The company’s first product, Endomina, a triangulation system for use during GI endoscopic procedures. The system allows gastroenterologists to perform endoscopic suturing similar to laparoscopic interventions, using only natural orifices. Funds from the round will be used to submit for regulatory approval in the US for the Endomina system and support R&D for new products and indications. Key strategics in the endoscopy market include Karl Storz, Olympus, and Richard Wolf.
Neurent Medical – a novel RF device for the relief of chronic rhinitis symptoms
The Neuromark System applies low-power radiofrequency (RF) energy to targeted regions in the nasal cavity that interrupt parasympathetic nerve signals. By disrupting these signals, the body’s inflammatory response is halted, preventing core symptoms of chronic rhinitis. Recently the company closed a Series B round which raised approximately $25M in capital. To-date the company has raised an estimated $36.3M. Major competitors in the ENT market include Medtronic, Smith & Nephew, and Stryker.
BreathSuite is improving respiratory care for patients with inhalers
Improper utilization and poor adherence result in lower quality of life among patients that require an inhaler. To address these unmet needs, BreatheSuite has developed a small add-on for inhalers and an application for patients that provides patients with real-time feedback and guidance for use with their device. In January 2021, the company completed a Seed round of fundraising to support commercialization of their product throughout North America and develop new inhaler add-on products.
EBR Systems – overcoming the limitations of current implantable devices for the treatment of heart failure
The company is developing the WiSE cardiac resynchronization therapy (CRT) system, which uses ultrasound energy to pace the heart from inside the left ventricle. This approach is believed to be more physiologic than current CRT systems which pace the heart from outside the left ventricle. The WiSE CRT system was granted Breakthrough Device Designation Status from the FDA in September 2019. Boston Scientific, Medtronic, and MicroPort are major competitors in the heart failure therapeutics market.
EBR Systems will be presenting at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Neuros Medical is developing a solution for residual nerve pain in amputees
Residual “phantom” pain is a common complication in post-amputee patients. To address this complication, Neuros Medical is developing an implantable device that delivers high-frequency electrical signals to block pain signals in post-amputation patients. The technology has wider applications for the treatment of post-surgical pain and migraine-induced pain. In January 2021, the company closed a Series B round which raised approximately $38.5M in capital. With the completion of this recent round, the company has raised an estimated $79M in funding to-date. Top competitors in the neurostimulation market include Abbott, LivaNova, and SPR Therapeutics.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.